Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21
Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21
AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.
得克萨斯州奥斯汀，2024年5月16日（GLOBE NEWSWIRE）——专注于开发妇科疾病诊断工具的生物分析女性健康公司Aspira Women's Health Inc.（“Aspira” 或 “公司”）（纳斯达克股票代码：AWH）今天宣布，管理层将在2024年5月21日星期二虚拟举行的联盟全球合作伙伴医疗保健展示会上介绍公司概况。
|
Presentation Details: | |
| Date: | Tuesday, May 21, 2024 |
| Time: | 11:00 am EST |
| Webcast: | Click HERE to register for the conference and view the presentation |
| 演示详情： | |
| 日期： | 2024 年 5 月 21 日，星期二 |
| 时间： | 美国东部标准时间上午 11:00 |
| 网络直播： | 点击这里 注册会议并查看演示文稿 |
Management will be available for one-on-one meetings with investors who are registered for the conference.
管理层将可以与注册参加会议的投资者进行一对一的会面。
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
关于 Aspira 女性健康公司
Aspira Women's Health Inc. 致力于发现、开发和商业化基于人工智能的无创检测，以帮助诊断妇科疾病。
OvaWatch and Ova1Plus are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women planned for surgery.
OvaWatch 还有 Ova1Plus 作为 ovaSuite 提供给临床医生军士长。他们共同提供唯一全面的血液检查产品组合，以帮助每年被诊断患有附件肿块的120多万美国女性发现卵巢癌。OVAWatch提供的阴性预测值为99％，用于评估女性的卵巢癌风险，初步临床评估表明肿块不确定或良性，因此手术可能为时过早或不必要。Ova1Plus 包含两项经美国食品药品管理局批准的测试，即 Ova1 和 Overa，以评估计划接受手术的女性患卵巢恶性肿瘤的风险。
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
我们正在开发的测试管道旨在扩大我们的卵巢癌产品组合，满足对子宫内膜异位症无创诊断的巨大需求，子宫内膜异位症是一种影响全球数百万女性的使人衰弱的疾病。在卵巢癌中，我们的 OvamdX军士长 风险评估旨在将microRNA和蛋白质生物标志物与患者数据相结合，以进一步提高我们当前测试的灵敏度和特异性。在子宫内膜异位症中，EndoCheck军士长 是有史以来第一项旨在识别子宫内膜瘤的无创检测，子宫内膜瘤是最常见的子宫内膜异位症形式之一。EndomDX军士长 该测试旨在将microRNA和蛋白质生物标志物与患者数据相结合，以识别所有子宫内膜异位症。
Investor Relations Contact:
Torsten Hombeck, Ph.D.
Chief Financial Officer
Aspira Women's Health
Investors@aspirawh.com
投资者关系联系人：
托斯滕·霍姆贝克博士
首席财务官
Aspira 女性健康
Investors@aspirawh.com